Skip to main content

EDP Biotech Corporation

Advanced Assays for Colorectal Cancer & More
Home
About Us
Clinical Trials
Colorectal Cancer
Contact EDP
EDP100, 200 Biomarker
EDP Privacy Policy
Management Team
Member Login
Scientific Advisory Board
Site Map
Home
 
 EDP at Medica 2010 Pictured Below

EDP Biotech Corporation is a privately held medical device company focused on the development and commercialization of blood based immunodiagnostic assays incorporating EDP100 and EDP200 biomarkers. EDP100  and EDP200 Biomarkers are fully characterized, incorporated into Enzyme-Linked Immunosorbent Assays (ELISA) and undergoing various IRB Sanctioned Trials to confirm "clinical utility" for specfic Oncology Disease States.  EDP100 and EDP200 Biomarker IP (Intellectual Property) is Patent Pending.*  These tests are not available or approved for public diagnostic screening at this time. 
 
 
EDP's biomarker identifies specific proteins at pre-symptomatic stages known to be elevated within the blood of individuals harboring certain cancers.
 
*EDP Biotech Corporation's IP is represented and managed by Merchant & Gould
EDP Biotech Colomarker
The discovery and development of new revolutionary biomarkers, EDP100 and EDP200, may provide patients and physicians with an easier method to screen for a variety of cancers. Based on pre-clinical studies, EDP100 and EDP200 when configured into an ELISA Immunoassay targeting specific cancers has shown promising results in detecting certain cancers at very early pre-stage 1 levels when these cancers are most treatable.
 

EDP's ELISA test detects the level of EDP100 and EDP200 proteins found in the blood. While these proteins are naturally occuring in blood serum, they become elevated levels when certain cancerous tumors are present. When clinical results are confirmed with further studies and FDA clearance is obtained, this new in vitro diagnostic test will be the first in a series of screens providing patients with a more convenient, accurate method of early cancer screening.  The first application of the EDP100 and EDP200 Biomarkers is for Colorectal Cancer (CRC).

 
 
EDP Biotech
6701 Baum drive
Suite 110
Knoxville, TN  37919
PH (USA):  865-246-0514